TBMED: Successful Completion of 18 Project Months
Creating an Open Innovation test bed for the development of high-risk medical devices
It is amazing how time flies: the first 18 months of our TBMED project are already over. The end of the first project period came along with a review meeting which, contrary to our plans at the beginning of the year, had to be held online as we could not re-unite in Brussels and meet with the European Commission in person. A few months into the COVID-19 crisis, we are, however, experts in online meetings and were well prepared to face this additional challenge.
The TBMED partners seized the opportunity to show their progress from a business planning perspective with regard to actually developing the future Open Innovation test bed (OITB), as well from a scientific perspective in terms of sharing insights into their medical device developments. The work with the project-internal use cases on Keratoprosthesis, Glycobone and hyperthermia treatment are considered a valuable contribution for building the OITB, as the planned services are applied and tested with regard to their feasibility. In the end, this will help to provide better services to the project's future customers.
TBMED aims to support European med-tech companies in global competition by reducing the time-to-market of high-risk medical devices (MD). An Open Innovation test bed for the development of devices of risk classification IIb and higher will provide expert support from an early development stage to the optimised transformation of prototypes into valuable and innovative products. As one of the 13 European partners from Spain, France, Ireland and Germany, Eurice supports the TBMED consortium in the field of project and innovation management as well as in the coordination and implementation of the project's dissemination and communication activities.
